Rein Therapeutics (RNTX) announced that it has received orphan drug designation from the European Medicines Agency, EMA, for LTI-03, its lead drug candidate aimed at preserving lung function in patients with idiopathic pulmonary fibrosis, IPF. The designation follows a positive opinion from the EMA’s Committee for Orphan Medicinal Products, COMP, and subsequent adoption by the European Commission.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNTX: